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SELECTION OF THE MONTH 
Title of the Month: Big Title: Juan Rodes (1938-2017) [Joel, please confirm that the 
obituary will be published in the April issue 
 
Small titles 
New therapy for Portal hypertension 
miRNA-206 and fecal microbiota in fatty liver diseases 
 
ACUTE LIVER INJURY 
Protective action of coagulation in acetaminophen (APAP)-induced liver injury 
APAP-induced liver injury is associated with the activation of the blood coagulation 
cascade but the consequences of this are not understood. Here Kopec et al. reveal a 
novel pathway of liver repair after APAP overdose in mice; fibrin(ogen) engages 
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αMβ2 integrin expressed at leukocyte surface to stimulate production of 
macrophage metalloelastase (encoded by Mmp12), that protects against liver 
injury after APAP overdose. Studies on the role of coagulation activation in APAP 
overdose in humans are needed. 
 
LIVER FIBROSIS 
Transcriptional control of hepatic stellate cell (HSC) activation 
Transcription factors (TFs) that control HSC transdifferentiation into activated 
myofibroblasts is a crucial event in hepatic fibrogenesis. Here, Cena et al. investigate 
the role of the transcription factor called COUP (for Chicken Ovalbumin Upstream 
Promoter) transcription factor 2 (short name COUP-TF2; encoded by NR2F2) in HSC 
activation and in the multifunctional role of HSCs during the response to liver injury. 
They show that in HSC, COUP transcription factor 2 is involved in the acquisition 
of a hypoxia-independent proangiogenic phenotype and regulates the paracrine 
signals between HSC and sinusoidal endothelial cells during hepatic wound 
healing. It is interesting to note that COUP-TF2 is a ligand-activated transcription 
factor; ligands being metabolites of retinol (i.e., vitamin A) such as 9-cis-retinoic acid 
and all-trans-retinoic acid (ATRA). The liver plays a central role in the production of 
ATRA which is the biologically active form of retinol with multiple functions including 
stem cell differentiation, macrophage polarization, among others. Future studies 
should explore the link between vitamin A metabolism and HSC activation. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Mutated DICER1, C-C motif chemokine 5 drives HCC 
There is evidence that genetic predisposition increases the risk of developing HCC, 
independently of other risk factors. Caruso et al. were interested in mutations in dicer 
1, ribonuclease III (DICER1, encoding the endoribonuclease Dicer) in the context of 
HCC. This is because it is a double-stranded RNA (dsRNA) endoribonuclease which 
plays a central role in short dsRNA-mediated post-transcriptional gene silencing. It 
cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNAs) 
into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two 
nucleotides, producing respectively short interfering RNAs (siRNA) and mature 
microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing 
complex (RISC) to complementary RNAs to degrade them or prevent their translation. 
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Gene silencing mediated by siRNAs, also called RNA interference, controls the 
elimination of transcripts from mobile and repetitive DNA elements of the genome but 
also the degradation of exogenous RNA of viral origin for instance. The miRNA 
pathway on the other side is a mean to specifically regulate the expression of target 
genes. Caruso et al. reveal the role of DICER1 mutations in liver carcinogenesis 
in a specific subtype of familial and sporadic HCCs associated with ß-catenin 
activation. In sporadic cases, some mature miRNAs were specifically downregulated 
raising the possibility of an important role of small non-coding RNAs in the liver 
carcinogenesis.  
Liver inflammation plays a crucial role in the progression of fibrosis and promotes liver 
cancer. The inflammatory signals involved in these effects are poorly known. Mohs et 
al. now show that C-C motif chemokine 5 (also known as T-cell-specific protein 
RANTES and encoded by CCL5) is an important mediator for liver carcinogenesis. 
This chemokine and its receptor (C-C chemokine receptor type 5) as well is 
overexpressed in liver tissues from patients with chronic liver disease. In a mouse 
model of HCC, Ccl5 deletion resulted in reduced number of infiltrating immune cells 
(granulocytes, inflammatory monocytes and CD4+ and CD8+ T cells) and development 
of tumors (that were smaller and less proliferative as compared to tumors in wild type 
mouse). The Authors identify hematopoietic cells as major source of C-C motif 
chemokine 5. Together these findings illuminate the role of inflammatory cues and 
effector cells related to innate and adaptive immunity in HCC promotion. They suggest 
that C-C motif chemokine 5 and signaling pathways could be a target for novel 
therapeutic approaches in patients with HCC. 
 
FATTY LIVER DISEASES 
MicroRNA and microbiota in the pathogenesis of non-alcoholic and alcoholic 
fatty liver disease 
Insulin resistance and lipogenesis play an important role in NAFLD. Identifying the 
underlying molecular drivers could result in novel targeted therapies. In this issue of 
the Journal, Wu et al. studied the implication of microRNA-206 (miR-206), a key 
regulator of many pathophysiological processes in humans. Delivery of miR-206 into 
the livers of obese mice resulted in the strong therapeutic effects on 
hepatosteatosis and hyperglycemia. By interacting with polyribonucleotide 
nucleotidyltransferase (PTPN1) and modulating lipogenesis and insulin signaling, 
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miR-206 reduced lipid and glucose production in human hepatocytes and livers of 
obese mice. This intriguing study reinforces the important regulatory properties of 
microRNA in fatty liver diseases and suggest that miR-206 could be novel therapeutic 
target for fatty liver and type 2 diabetes. This issue contains another interesting study 
on the pathogenesis of fatty liver disease. In particular, the paper by Ferrere at al. 
investigated the implication of fecal microbiota in alcoholic liver disease. This study is 
very timely since fecal transplantation is currently being tested in patients with alcoholic 
hepatitis. The authors used alcohol-sensitive and resistant mice two to test the 
efficiency of two complementary strategies (fecal microbiota transplantation and 
prebiotic treatment) to reverse dysbiosis and prevent alcoholic liver disease. Ethanol 
induced steatosis and liver inflammation, which were associated with disruption of gut 
homeostasis, in alcohol-sensitive, but not alcohol-resistant mice. Interestingly, the 
fecal content of Bacteroides was in alcohol-sensitive mice. By treating mice with 
pectin, which induced major modifications of the microbiota, or fecal microbiota 
transplantation, which resulted in a microbiota similar to that in resistant donor mice, 
the authors were able to prevent liver inflammation and restore gut homeostasis. 
This study confirms the recent studies in patients with alcoholic hepatitis showing that 
manipulation of fecal microbiota can prevent alcohol-induced liver injury. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
HCV type 2 – not so weak, DAAs in kidney transplant recipients, the unhappy 
few – resistance analysis of DAA failure patients  
HCV type 2 has been typically considered to be a weak genotype, easy to cure even 
with a short-term interferon-based regimen. First studies evaluating interferon-free 
sofosbuvir-based regimens seemed to confirm this typical feature as sofosbuvir given 
for only 12 weeks and boosted only by ribavirin was sufficient to cure nearly all HCV 
type 2-infected patients. However, real life cohorts showed lower cure rates, especially 
in patients with cirrhosis and in those with intergenotypic viral chimeras - recombinant 
HCV genotype 2k/1b strains -, not recognized by the commonly used genotyping 
assay. Mangia et al. now investigated the effect of extending sofosbuvir plus ribavirin 
treatment duration to 16-20 weeks in a large Italian real life HCV type 2-infected cohort 
with bridging fibrosis or cirrhosis. Cure rates in those with cirrhosis were 95% after 
16 or 20 weeks of treatment, respectively, and 99% in those with bridging 
fibrosis. No 2k/1b strains were identified in this Italian cohort. The study highlights the 
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need for extending sofosbuvir/ribavirin treatment duration beyond 12 weeks in HCV-
type 2-infected patients with advanced fibrosis especially in those countries in which 
more robust pangenotypic regimens containing sofosbuvir plus ledipasvir are not 
available. 
The study by Fernández et al. is one of largest evaluating interferon-free direct-acting 
antivirals in HCV-infected kidney transplant patients prospectively collected in a 
Spanish registry (Hepa-C). Among the 103 patients treated mainly with sofosbuvir plus 
either ledipasvir or daclatasvir ± ribavirin, cure rates were 98%. Dose adjustment of 
the immunosuppressive regimen was required in 55%, and 16% of the patients’ 
experienced renal dysfunction, a side effect that was associated with the presence of 
cirrhosis. The study shows that being kidney transplanted has no negative impact 
on the efficacy of the direct-acting antiviral (DAA) regimens, but a non-negligible 
number of patients, most of them cirrhotic, developed mild allograft dysfunction 
and a significant proportion of patients required immunosuppression dose 
adjustment, warranting a close follow-up during therapy. 
The small proportion of patients who fail treatment with potent DAA regimens are at 
high risk to harbor viral variants with drug-resistance associated substitutions (RAS). 
With the aim to characterize drug resistance, Wyles et al. performed HCV NS5A and 
NS5B deep sequencing in HCV type 1-infected who participated in the large 
ledipasvir/sofosbuvir phase 2 and 3 clinical trials (N=2,144). The majority of patients 
with virologic failure (74.5%) had detectable ledipasvir-specific NS5A RAS (75%), 
and many of them had ledipasvir RASs at baseline. In contrast, resistance to 
sofosbuvir was uncommon with only 3 patients showing detectable NS5B RAS. As the 
duration of treatment increased from 6 to 12, the proportion of patients with relapse 
decreased dramatically, while the proportion with RASs detected at the failure time 
point increased, suggesting that the reason for relapse following less than 12 weeks of 
treatment is mainly due to incomplete clearance of HCV, rather than selection of drug 
resistance. The persistence of NS5A RAS at high frequencies within the viral 
quasispecies for up to 96 weeks posttreatment is of relevant concern when considering 
re-treatment strategies in these unhappy few patients. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
Specific HBV entry inhibition by cyclosporine A derivatives, HBV interference 
with innate immunity 
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Inhibiting the HBV entry receptor sodium taurocholate cotransporting polypeptide 
(NTCP) represents a highly interesting approach to further improve the HBV treatment 
efficacy. NTCP inhibition, however, can impair its transporter activity for bile acid 
uptake, and thus may potentially cause significant adverse effects. The aim of the 
elegant study by Shimura S et al. was to identify small molecules that inhibit HBV entry 
but not affecting the NTCP transporter function. Several cyclosporine A derivatives 
were identified which effectively inhibit HBV attachment to host cells by directly 
interacting with the NTCP protein. Compounds were described that did not 
impair the NTCP dependent uptake of bile acids, suggesting that the anti-HBV 
activity can be functionally separated from bile acids transport. These intriguing 
findings may further stimulate HBV entry inhibition drug development.  
HBV has developed numerous mechanisms for interfering with the immune system 
and maintaining viral persistence. In the present study, Yu et al. demonstrated for the 
first time that HBeAg reduces lipopolysaccharide-induced NOD-like receptor (NLR; 
also known as nucleotide binding domain and leucine-rich repeat containing receptor)-
family pyrin domain-containing 3 (NLRP3) inflammasome activation and subsequent 
IL-1β secretion in Kupffer cells via suppressing NF-κB pathway and ROS production. 
This finding provides a novel mechanism for how HBeAg interferes with 
intracellular innate immune pathway to escape immune recognition, and 
contributes to the HBV persistence. The study also provides new therapeutic targets 
for chronic HBV infection and related diseases. 
 
PORTAL HYPERTENSION 
Farsenoid X receptor is a target for treatment of portal hypertension  
In cirrhotic patients, the severity of portal hypertension is closely associated with 
progression to decompensation and increased mortality. Therapeutic options for the 
treatment of portal hypertension is limited to non-selective beta blockers, which has 
limited effectiveness and many patients find it difficult to tolerate. The paper by 
Schawbl et al. shows that, the non-steroidal FXR agonist PX20606, a drug in 
clinical development effectively reduces the severity of portal hypertension in 
two animal models confirming FXR as a therapeutic target. They also show, that 
the drug achieves this through effects on modulating the severity of fibrosis and 
mediators of intrahepatic resistance. Data from clinical trials are eagerly awaited. 
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LIVER TRANSPLANTATION 
Alloantigen gene transfer to hepatocytes promotes tolerance to allogenic graft 
Donor major histocompatibility complex (MHC) molecules represent the main targets 
of the allogeneic immune response of patients who receive a transplant. Induction of 
immune tolerance to donor is a good alternative to chronic life-long 
immunosuppression for these patients. Le Guen et al. are the first to show that adeno-
associated viral-mediated long-term expression of a single MHC class I molecule in 
the liver induces the generation of a subset of allospecific CD8+ regulatory T cells, 
which promote tolerance toward fully allogeneic graft. They conclude that liver gene 
transfer represents a promising strategy for in vivo induction of donor-specific 
tolerance. 
